<p>藥明康德（NASDAQ:DVAX - 獲取免費報告）於週三發佈了季度財報。這家生物製藥公司報告本季度每股收益（EPS）為 0.21 美元，超出分析師一致預期的 0.14 美元，超出幅度為 0.07 美元，Zacks 報道。該公司本季度的收入為 9488 萬美元，而一致預期為 9400 萬美元。藥明康德的股本回報率為 5.10%，淨利潤率為-16.67%。</p>
<p>獲取 <strong>藥明康德</strong> 的提醒：</p>
<h2>藥明康德股票表現</h2>
<p>週三，NASDAQ DVAX 在交易時段上漲 0.25 美元，達到 10.30 美元。該股票交易量為 2,378,061 股，而其平均交易量為 1,977,836 股。藥明康德的 12 個月低點為 9.20 美元，12 個月高點為 14.63 美元。該股票的 50 日移動平均為 9.99 美元，200 日移動平均為 10.28 美元。公司的市值為 12.1 億美元，市盈率為-22.39，貝塔值為 1.09。公司的速動比率為 6.01，流動比率為 6.65，債務股本比率為 0.45。</p>
<h2>藥明康德的內部交易</h2>
<p>在其他藥明康德的新聞中，董事 Scott Dunseth Myers 於 8 月 22 日（星期五）購買了 3,800 股該公司的股票。該股票的平均購買價格為每股 10.82 美元，總價值為 41,116.00 美元。購買後，該董事在公司持有 35,004 股，估值約為 378,743.28 美元。這代表其持股比例增加了 12.18%。該交易已在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站獲取。內部人士持有公司 2.98% 的股票。</p>
<h2>機構資金流入和流出</h2>
<p>最近，一些機構投資者和對沖基金買賣了 DVAX 的股票。Osaic Holdings Inc.在第二季度將其在藥明康德的持股增加了 15.1%。Osaic Holdings Inc.目前持有 9,336 股生物製藥公司的股票，價值 93,000 美元，此前在該期間內又購買了 1,226 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在藥明康德的持股增加了 1.9%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 86,421 股生物製藥公司的股票，價值 1,126,000 美元，此前在上個季度又購買了 1,625 股。E Fund Management Co. Ltd.在第二季度將其在藥明康德的持股增加了 17.9%。E Fund Management Co. Ltd.目前持有 18,113 股生物製藥公司的股票，價值 180,000 美元，此前在上個季度又購買了 2,752 股。Envestnet Asset Management Inc.在第三季度將其在藥明康德的持股增加了 55.3%。Envestnet Asset Management Inc.目前持有 20,888 股生物製藥公司的股票，價值 207,000 美元，此前在該期間內又購買了 7,441 股。最後，Tower Research Capital LLC TRC 在第二季度將其在藥明康德的持股增加了 319.8%。Tower Research Capital LLC TRC 目前持有 16,239 股生物製藥公司的股票，價值 161,000 美元，此前在上個季度又購買了 12,371 股。機構投資者和對沖基金持有公司 96.96% 的股票。</p>
<h2>分析師評級調整</h2>
<p>最近，一些券商對 DVAX 發表了評論。華爾街 Zen 在 8 月 9 日的報告中將藥明康德的股票評級從 “持有” 上調至 “買入”。JMP Securities 在 8 月 22 日的報告中重申了 “市場表現優於大盤” 的評級，並對藥明康德的股票設定了 32.00 美元的目標價。最後，Weiss Ratings 在 10 月 8 日的報告中重新發布了藥明康德的 “賣出（d）” 評級。三位分析師對該股票給予了買入評級，兩位分析師給予了賣出評級。根據 MarketBeat.com 的數據，藥明康德目前的平均評級為 “持有”，共識目標價為 24.33 美元。</p>
<p><strong>獲取我們關於 DVAX 的最新報告</strong></p>
<h2>藥明康德公司簡介</h2>
<p>（獲取免費報告）</p>
<p>藥明康德公司是一家商業階段的生物製藥公司，專注於在美國開發和商業化疫苗。它在美國和歐洲市場銷售 HEPLISAV-B，這是一種用於預防所有已知亞型的乙型肝炎病毒感染的乙型肝炎疫苗，適用於 18 歲及以上人羣。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是藥明康德</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>目前有 3 只現金充裕的股票具有高增長潛力</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>為什麼垂直航空股票在這次飛行測試後可能會翻倍</li>
<li>如何找到值得投資和交易的便士股票</li>
<li>亞馬遜：突破確認——它可能接下來會去哪裏</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
<p>在你考慮藥明康德之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而藥明康德並不在名單上。</p>
<p>雖然藥明康德目前在分析師中評級為持有，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

德納維制藥

<p>德納維製藥（NASDAQ:DVAX）報告的季度每股收益為 0.21 美元，超出預期 0.07 美元。該公司實現收入 9488 萬美元，超過市場共識預期的 9400 萬美元。儘管淨利潤率為負的 16.67%，但其股本回報率為正的 5.10%。股票交易價格為 10.30 美元，市值為 12.1 億美元。分析師的評級意見不一，三位分析師推薦買入，二位分析師推薦賣出，平均目標價為 24.33 美元</p>

<p>Dynavax Technologies (NASDAQ:DVAX - Get Free Report) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.07, Zacks reports. The firm had revenue of $94.88 million for the quarter, compared to the consensus estimate of $94.00 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.</p>
<div class="lb-trans"><p>藥明康德（NASDAQ:DVAX - 獲取免費報告）於週三發佈了季度財報。這家生物製藥公司報告本季度每股收益（EPS）為 0.21 美元，超出分析師一致預期的 0.14 美元，超出幅度為 0.07 美元，Zacks 報道。該公司本季度的收入為 9488 萬美元，而一致預期為 9400 萬美元。藥明康德的股本回報率為 5.10%，淨利潤率為-16.67%。</p>
</div><p>Get <strong>Dynavax Technologies</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>藥明康德</strong> 的提醒：</p>
</div><h2>Dynavax Technologies Stock Performance</h2>
<div class="lb-trans"><h2>藥明康德股票表現</h2>
</div><p>NASDAQ DVAX traded up $0.25 during trading hours on Wednesday, hitting $10.30. 2,378,061 shares of the stock were exchanged, compared to its average volume of 1,977,836. Dynavax Technologies has a 12-month low of $9.20 and a 12-month high of $14.63. The stock has a 50-day moving average of $9.99 and a 200 day moving average of $10.28. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -22.39 and a beta of 1.09. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45.</p>
<div class="lb-trans"><p>週三，NASDAQ DVAX 在交易時段上漲 0.25 美元，達到 10.30 美元。該股票交易量為 2,378,061 股，而其平均交易量為 1,977,836 股。藥明康德的 12 個月低點為 9.20 美元，12 個月高點為 14.63 美元。該股票的 50 日移動平均為 9.99 美元，200 日移動平均為 10.28 美元。公司的市值為 12.1 億美元，市盈率為-22.39，貝塔值為 1.09。公司的速動比率為 6.01，流動比率為 6.65，債務股本比率為 0.45。</p>
</div><h2>Insider Transactions at Dynavax Technologies</h2>
<div class="lb-trans"><h2>藥明康德的內部交易</h2>
</div><p>In other Dynavax Technologies news, Director Scott Dunseth Myers bought 3,800 shares of the business's stock in a transaction dated Friday, August 22nd. The stock was acquired at an average cost of $10.82 per share, with a total value of $41,116.00. Following the purchase, the director owned 35,004 shares in the company, valued at approximately $378,743.28. This represents a 12.18% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 2.98% of the company's stock.</p>
<div class="lb-trans"><p>在其他藥明康德的新聞中，董事 Scott Dunseth Myers 於 8 月 22 日（星期五）購買了 3,800 股該公司的股票。該股票的平均購買價格為每股 10.82 美元，總價值為 41,116.00 美元。購買後，該董事在公司持有 35,004 股，估值約為 378,743.28 美元。這代表其持股比例增加了 12.18%。該交易已在向 SEC 提交的文件中披露，相關文件可通過 SEC 網站獲取。內部人士持有公司 2.98% 的股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of DVAX. Osaic Holdings Inc. lifted its holdings in Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,226 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Dynavax Technologies by 1.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company's stock valued at $1,126,000 after purchasing an additional 1,625 shares in the last quarter. E Fund Management Co. Ltd. increased its holdings in shares of Dynavax Technologies by 17.9% in the 2nd quarter. E Fund Management Co. Ltd. now owns 18,113 shares of the biopharmaceutical company's stock valued at $180,000 after purchasing an additional 2,752 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Dynavax Technologies by 55.3% in the third quarter. Envestnet Asset Management Inc. now owns 20,888 shares of the biopharmaceutical company's stock valued at $207,000 after purchasing an additional 7,441 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in Dynavax Technologies by 319.8% during the second quarter. Tower Research Capital LLC TRC now owns 16,239 shares of the biopharmaceutical company's stock worth $161,000 after buying an additional 12,371 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company's stock.</p>
<div class="lb-trans"><p>最近，一些機構投資者和對沖基金買賣了 DVAX 的股票。Osaic Holdings Inc.在第二季度將其在藥明康德的持股增加了 15.1%。Osaic Holdings Inc.目前持有 9,336 股生物製藥公司的股票，價值 93,000 美元，此前在該期間內又購買了 1,226 股。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在藥明康德的持股增加了 1.9%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 86,421 股生物製藥公司的股票，價值 1,126,000 美元，此前在上個季度又購買了 1,625 股。E Fund Management Co. Ltd.在第二季度將其在藥明康德的持股增加了 17.9%。E Fund Management Co. Ltd.目前持有 18,113 股生物製藥公司的股票，價值 180,000 美元，此前在上個季度又購買了 2,752 股。Envestnet Asset Management Inc.在第三季度將其在藥明康德的持股增加了 55.3%。Envestnet Asset Management Inc.目前持有 20,888 股生物製藥公司的股票，價值 207,000 美元，此前在該期間內又購買了 7,441 股。最後，Tower Research Capital LLC TRC 在第二季度將其在藥明康德的持股增加了 319.8%。Tower Research Capital LLC TRC 目前持有 16,239 股生物製藥公司的股票，價值 161,000 美元，此前在上個季度又購買了 12,371 股。機構投資者和對沖基金持有公司 96.96% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>A number of brokerages have recently commented on DVAX. Wall Street Zen raised shares of Dynavax Technologies from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, August 9th. JMP Securities reaffirmed a &#34;market outperform&#34; rating and issued a $32.00 target price on shares of Dynavax Technologies in a report on Friday, August 22nd. Finally, Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Dynavax Technologies presently has an average rating of &#34;Hold&#34; and a consensus price target of $24.33.</p>
<div class="lb-trans"><p>最近，一些券商對 DVAX 發表了評論。華爾街 Zen 在 8 月 9 日的報告中將藥明康德的股票評級從 “持有” 上調至 “買入”。JMP Securities 在 8 月 22 日的報告中重申了 “市場表現優於大盤” 的評級，並對藥明康德的股票設定了 32.00 美元的目標價。最後，Weiss Ratings 在 10 月 8 日的報告中重新發布了藥明康德的 “賣出（d）” 評級。三位分析師對該股票給予了買入評級，兩位分析師給予了賣出評級。根據 MarketBeat.com 的數據，藥明康德目前的平均評級為 “持有”，共識目標價為 24.33 美元。</p>
</div><p><strong>Get Our Latest Report on DVAX</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 DVAX 的最新報告</strong></p>
</div><h2>Dynavax Technologies Company Profile</h2>
<div class="lb-trans"><h2>藥明康德公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.</p>
<div class="lb-trans"><p>藥明康德公司是一家商業階段的生物製藥公司，專注於在美國開發和商業化疫苗。它在美國和歐洲市場銷售 HEPLISAV-B，這是一種用於預防所有已知亞型的乙型肝炎病毒感染的乙型肝炎疫苗，適用於 18 歲及以上人羣。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Dynavax Technologies</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>3 Cash-Rich Stocks With High Growth Potential Right Now</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>Why Vertical Aerospace Stock Could Double After This Flight Test</li>
<li>How to find penny stocks to invest and trade</li>
<li>Amazon: Breakout Confirmed—Here’s Where It Could Go Next</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是藥明康德</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>目前有 3 只現金充裕的股票具有高增長潛力</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>為什麼垂直航空股票在這次飛行測試後可能會翻倍</li>
<li>如何找到值得投資和交易的便士股票</li>
<li>亞馬遜：突破確認——它可能接下來會去哪裏</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=DVAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Dynavax Technologies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
</div><p>Before you consider Dynavax Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮藥明康德之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而藥明康德並不在名單上。</p>
</div><p>While Dynavax Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然藥明康德目前在分析師中評級為持有，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

德納維製藥（NASDAQ:DVAX）公佈季度財報，每股收益超出預期 0.07 美元